Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
1 2 3 ... 19 20 21 ... 54 55 56

Deal: Collaboration or Financing	Date
Myelo Therapeutics–SEVERAL: investment, 201512 financing round Series B incl VC Fonds Technologie Berlin + ELSA + JSC Valenta + Vladimir Nebolsin	2015-12-15
Neovacs–ActeaVentures: business consulting, 201512 supply service business development advisor for Neovacs license deal w Chong Kun Dang	2015-12-15
Photonis–MasCom: electron multiplier, 201512– supply by MasCom of multipliers for ICP-MS + resale by Photonis USA	2015-12-15
Sanofi–Boehringer: investment, 201512–201701 acquisition €11.4b of Merial animal health business by BI	2015-12-15
BPCE–Novartis: investment, 201512 strategic investment of Novartis Pharma AG in Health for Life Capital Fund increasing available funds to €160m	2015-12-14
Caltech–Thermo Fisher: mass spectrometer, 201512 supply existent new 253 Ultra HR-IRMS at lab of John Eiler	2015-12-14
Complix–Selexis: biological contract manufacturing, 201512– supply SUREtechnology platform to enable production of Alphabody candidate CMX-02	2015-12-14
ETH Zürich–Thermo Fisher: mass spectrometer, 201512 supply existent new 253 Plus 10kV IRMS at lab of Stefano Bernasconi	2015-12-14
Inthera Bioscience–SEVERAL: investment, 201512 seed financing round €3.4m led by MS Ventures incl Aglaia + Novo Seeds + EVA Basel	2015-12-14
NovaPump–SEVERAL: investment, 201512 financing round with bm\|t + Sparkasse Jena-Saale-Holzland	2015-12-14
Sanofi–MAB Discovery: therapeutic antibodies, 201512– collab €na developm MAbs against selected Sanofi targets	2015-12-14
Genetrix (ES)–SEVERAL: investment, 201512 rights offering + private placement of Sygnis AG €5.6m with 2.963m new shares €1.9/share	2015-12-10
Basilea–SEVERAL: credit, 201512 senior unsecured convertible bonds CHF200m with coupon of 2.75% per annum due 2022	2015-12-09
Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd	2015-12-09
Wilex–Hopp Group: investment, 201512 investment €1.712m w 930,560 new shares at €1.84/share dievini Hopp BioTech holding	2015-12-09
Wilex–SEVERAL: investment, 201512 investment €815k w 443,124 new shares at €1.84/share to existent shareholders	2015-12-09
BASF–Evogene: herbicides, 201512–201811 collab 3y r+d novel herbicides using Evogene’s computational discovery approach	2015-12-08
Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint	2015-12-08
Roche–Pieris: cancer immunotherapy, 201512– collab + license ww up to CHF415m + royalties r+d of Anticalin-based drugs against Roche target	2015-12-08
Max Planck–Bruker Corp: mass spectrometry s/w, 201512 supply Prof Baldwin at MPI ICE Jena early user of MetaboScape s/w to mine complex plant genomics	2015-12-07
Roche–SQZ Biotech: cell therapy, 201512– collab over €500m in upfront+milestones plus royalties developm SQZ technology in oncology	2015-12-07
Kuros–Cytos Biotechnology: investment, 201512–201601 reverse merger acquisition CHF160m of Kuros Biosurgery by Cytos to be renamed Kuros Biosciences	2015-12-03
Kuros–Homburger: legal services, 201512 supply service legal advisor w regard to reverse merger acquisition CHF160m of Kuros Biosurgery by Cytos	2015-12-03
Lucigen–Genetrix (ES): genomic reagents, 201512– distribution of Sygnis TruePrime + SunScript RT products for clinical oncology research in US	2015-12-03
Shuwen Biotech–BioNTech: molecular diagnostics, 201512– collab clin developm + excl distribution rights for MammaTyper test in China	2015-12-03
Boehringer–Univ Texas: cancer drugs, 201512– collab discovery therapeutic concepts for pancreatic cancer w MD Anderson Cancer Center	2015-12-02
Ferring–TxCell: T-cell therapy, –201512 collab + excl option to in-license Ovasave for developm + comercialisation 12/15 TxCell RE-ACQUIRED RIGHTS	2015-12-02
Jennewein Biotechnologie–EU (govt): credit, 201512– loan €10m with equity-type transaction under InnovFin scheme from EIB	2015-12-02
Mayflower Bioscience–Genetrix (ES): genomic reagents, 201512– distribution of Sygnis TruePrime + SunScript RT products in US	2015-12-02
Santhera–Homburger: legal services, 201512 supply service Homburger legal advisor for CHF54.8m private placement	2015-12-02
Amcure–Germany (govt): grant, 201512 BMBF research grant €1.9m to advance lead candidate into clinic	2015-12-01
Amcure–MacDougall Biomedical Communications: public relations, 201512 service existent by MacDougall	2015-12-01
Gene Predictis–OTHER: investment, 201512 1st external invesment CHF0.5m by a strategic investor from Swiss healthcare system	2015-12-01
MATURA Consortium–Protagen: personalised medicine, 201512– project member collab research treatment response predictors in rheumatoid arthritis	2015-12-01
Novartis–Polyphor: drug discovery services, 201512 collab RnD extension working towards nomination of PEN macrocycle drug candidate	2015-12-01
Santhera–SEVERAL: investment, 201512 capital increase CHF54.8m private placement 590k new shares CHF93/share	2015-12-01
Cypher Genomics–Human Longevity: investment, 201511 acquisition €na of Cypher Genomics by HLI	2015-11-30
Poli Group–Almirall: investment, 201511– acquisition 100% of Poli Group Holding by Almirall ANNOUNCED	2015-11-30
Alvogen–Insilico Biotechnology: bioinformatics, 201511– collab Alvotech using Insilico simulation s/w to develop biosimilars using mammalian cells	2015-11-27
TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare	2015-11-25
TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors	2015-11-25
BMS–Life Sciences Partners: venture capital, 201511– strategic collab identifying life sciences innovation in Europe incl BMS investment in LSP 5 fund	2015-11-24
Life Sciences Partners–BMS: investment, 201511 significant investment in LSP 5 fund by BMS as part of strategic collaboration	2015-11-24
Life Sciences Partners–Hume Brophy: public relations, 201511 service existent by Hume Brophy	2015-11-24
ObsEva–MacDougall Biomedical Communications: public relations, 201511 service existent by MacDougall	2015-11-23
ObsEva–SEVERAL: investment, 201511 financing round Series B CHF60m ($60m) incl HBM + NEA + Orbimed + Rock Springs + Sofinnova	2015-11-23
ObsEva–Kissei: oral GnRH antagonist, 201511– acquisition €na excl rights to develop + commericalise KLH-2109 outside of Asia	2015-11-20
Merck (DE)–Univ Cape Town: malaria drug, 201511– collab research with UCT H3D to develop anti-malarial drug candidates using Merck compound library	2015-11-19
Greiner–Oncgnostics: cervical cancer test, 201511– distribution of GynTect test by Greiner Bio-One in DACH + FR + GB + Benelux	2015-11-18
Novartis–Thermo Fisher: molecular companion diagnostics, 201511– collab developm NGS-based CDx for NSCLC with Pfizer	2015-11-18
Oncotest–Charles River: investment, 201511 acquisition of Oncotest GmbH for €34m in cash + €2m milestones	2015-11-18
Biophytis–LifeSci: public relations, 201511 service existent by LifeSci Advisors	2015-11-17
Kymab–Genedata: bioinformatics, 201511– license to Genedata Biologics for HT antibody discovery w Kymouse technology	2015-11-17
Molecular Health–Hopp Group: investment, 201511 private financing round totalling €25m led by existing investor Dievini	2015-11-16
Molecular Health–SEVERAL: investment, 201511 private financing round €25m led by existing investor Dievini	2015-11-16
Greiner–Scienion: print/spotting technology, 201511 collab integrating sciFlexarrayer techn w Genspeed platform for rapid Dx tests	2015-11-13
Curetis–CMS: legal services, 201511 service CMS advisor for Curetis IPO at Euronext Amsterdam + Brussels	2015-11-11
Kuros–SEVERAL: investment, 201511 2nd CHF5m closing from new + existeng investors bringing financing round to CHF20m	2015-11-11
Nestlé–ImaBiotech: mass spectrometry services, 201511– supply Multimaging services for Galderma’s drug development	2015-11-10
Pierre Fabre–EPFL: biochips, 201511– collab research use of biosensor chips in clinical drug development	2015-11-10
Blue Scientific–Bruker Corp: analytical instruments, 201511– distribution sales of Bruker Nano Surfaces products in Scandinavia by Blue Scientific	2015-11-06
Syngenta–DSM: microbial agricultural solutions, 201511– collab developm microbial-based solutions incl bio-controls + bio-pesticides + bio-stimulants	2015-11-06
Probiodrug–SEVERAL: investment, 201511 private placement €13.5m w 677k new shares at €20/share to Europ + US investors	2015-11-05
Roche–Polyphor: antibiotic, 201311–201511 license excl ww to POL7080 CHF35m upfront + CHF465m milestones + royalties TERMINATED by Roche 11/15	2015-11-04
CureVac–Baillie Gifford: investment, 201511 private placement totalling €100m incl new + lead investor Baillie Gifford	2015-11-03
CureVac–Chartwave: investment, 201511 private placement totalling €100m incl new investor Chartwave Ltd	2015-11-03
CureVac–Coppel Group: investment, 201511 private placement totalling €100m incl new investor Coppel family	2015-11-03
CureVac–Elma Investments: investment, 201511 private placement totalling €100m incl new investor Elma Investments Ltd	2015-11-03
CureVac–Gates Foundation: investment, 201511 private placement totalling €100m incl existing investor Bill & Melinda Gates Foundation	2015-11-03
CureVac–Hopp Group: investment, 201511 private placement totalling €100m incl existing investor dievini Hopp Biotech Holding GmbH & Co KG	2015-11-03
CureVac–Rittershaus: legal services, 201511 supply legal advisor for €100m financing round	2015-11-03
CureVac–SEVERAL: investment, 201511 private placement €100m led by Baillie Gifford	2015-11-03
CureVac–Sigma Group: investment, 201511 private placement totalling €100m incl new investor Sigma Group	2015-11-03
Sanofi–BioNTech: cancer immunotherapy, 201511– collab + license agreement for mRNA-based therapeutics	2015-11-03
Wageningen Univ–Thermo Fisher: mass spectrometer, 201511 supply existent use of Q Exactive GC system by Marc Tienstra at RIKILT	2015-11-03
Lead Pharma–Akampion: public relations, 201511 service existent by Akampion	2015-11-02
Merck (DE)–Selvita: drug discovery services, 2013–2015 collab 2-year partnership in cancer metabolism	2015-11-02
Merck (DE)–Selvita: drug discovery services, 201511– collab €na 3-year r+d small-molecule cancer drugs	2015-11-02
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m	2015-11-02
Apta Biosciences–EU (govt): grant, 201511– Horizon 2020 grant €940k as part of MARA project to develop new antiinfectives	2015-11-01
BFCC project–EU (govt): grant, 201511– grant €3.6m for Baltic Fracture Competence Centre from Interreg Baltic Sea Region Programme	2015-11-01
BFCC project–Hamburg (govt): healthcare, 201511– Life Science Nord Management GmbH is lead partner in Baltic Fracture Competence Centre	2015-11-01
European AIDS Vaccine Initiative–EU (govt): grant, 201511– €23m Horizon 2020 grant for EAVI 2020 for 5 years to develop HIV vaccines	2015-11-01
MARA project–EU (govt): grant, 201511– Horizon 2020 grant €3m to develop new anti-infectives	2015-11-01
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund	2015-11-01
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m	2015-11-01
BioGenes–PERSON: investment, 201510 MBO €na from GUB Unternehmensbeteiligungen + VC Fonds Berlin by the two founders	2015-10-31
Co.don–SEVERAL: investment, 201510–201511 capital increase €5m with 2.5m new shares at €2/share w existing + new investors	2015-10-30
GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015	2015-10-29
High-Tech Gründerfonds–Donghai Securities: business services, 201510– collab service for accessing Chinese capital + markets	2015-10-29
Sigma-Aldrich–Olink: research reagents, 201510 acquisition of Duolink product portfolio by Sigma-Aldrich	2015-10-29
BioLamina–Cevec: rec protein production technology, 201510– license €na to CAP Go technology for laminins for ex vivo cell culture therapies	2015-10-28
Cevec–iBET (PT): rec protein production, 201510 collab existent GenIbet is joint venture partner of Cevec	2015-10-28
Curetis–Stratec: investment, 201510 existent Stratec Biomedical AG is existing investor	2015-10-28
Danaher–Univ Manchester: mass spectrometry, 201510– collab joint Sciex Multi-omics Centre for Precision Medicine tog w Stoller Centre	2015-10-28
Sias–Tecan: investment, 201510–201511 acquisition CHF25m in cash	2015-10-28
Univ Manchester–Danaher: mass spectrometer, 201510 supply Sciex QTRAP 6500+ Systems for MRM proteomics assays to Stoller Centre	2015-10-28
Univ Manchester–Danaher: mass spectrometer, 201510 supply Sciex TripleTOF 6600 Systems with SWATH Acquisition to Stoller Centre	2015-10-28
Agena Bioscience–Diatech: mass spec-based MDx, 201510– collab developm MassARRAY genomic CDx tests for cancer therapy w Diatech Pharmacogenetics Srl	2015-10-27
Biofrontera–SEVERAL: investment, 201510–201511 capital increase €3.64m net €3.1m with 1.92m new shares at €2/share	2015-10-27

1 2 3 ... 19 20 21 ... 54 55 56

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Advertise

Deals > All